Reviewing the safety of erlotinib in non-small cell lung cancer
Publication in refereed journal

Times Cited
Web of Science16WOS source URL (as at 26/11/2021) Click here for the latest count
Altmetrics Information

Other information
AbstractImportance of the field: Erlotinib, a potent inhibitor of EGFR activity, is approved as a monotherapy for the treatment of advanced NSCLC and in combination with gemcitabine for advanced pancreatic cancer. The oral administration and manageable toxicity of erlotinib, along with its similar efficacy to chemotherapy, make it an important option as either maintenance therapy or in second-/third-line for patients with NSCLC who have previously received first-line chemotherapy. It is also an emerging option in other treatment settings in NSCLC.
All Author(s) ListReck M, Mok T, Wolf J, Heigener D, Wu YL
Journal nameExpert Opinion on Drug Safety
Volume Number10
Issue Number1
PublisherTaylor & Francis: STM, Behavioural Science and Public Health Titles
Pages147 - 157
LanguagesEnglish-United Kingdom
KeywordsEGFR; erlotinib; NSCLC; TKI
Web of Science Subject CategoriesPharmacology & Pharmacy; PHARMACOLOGY & PHARMACY

Last updated on 2021-27-11 at 00:02